Xtant Medical shareholders approve board nominees and expand equity plan

Xtant Medical Holdings, Inc. (NYSE American:XTNT) announced the results of its annual meeting of stockholders held Friday, as reported in a press release statement based on a recent SEC filing.

Shareholders approved all six nominees to the board of directors. The elected directors are John K. Bakewell, Jonn R. Beeson, Sean E. Browne, Abhinav Jain, Tyler P. Lipschultz, and Stavros G. Vizirgianakis. Vote totals for each nominee ranged from approximately 79.1 million to 79.9 million shares in favor, with between 24,000 and 805,000 shares withheld. Broker non-votes totaled about 17 million shares for each nominee.

Stockholders also ratified the appointment of Grant Thornton LLP as the company’s independent registered public accounting firm for the year ending December 31, 2025, with 96.5 million votes for, 49,410 against, and 304,034 abstentions.

A key item on the agenda was the approval of an amendment to the Xtant Medical 2023 Equity Incentive Plan. The amendment increases the number of shares of common stock available under the plan by 12.3 million shares. The measure passed with 78.7 million votes in favor, 820,250 against, and 394,267 abstentions, while broker non-votes totaled 17 million shares.

Additionally, shareholders approved, on an advisory basis, the compensation of the company’s named executive officers with similar voting results. They also voted to hold future advisory votes on executive compensation every one year, with 78.7 million votes for the annual option, 1.08 million for two years, and 38,382 for three years.

As of the record date, September 9, 2025, Xtant Medical had approximately 140 million shares of common stock outstanding, with about 69.2% of shares represented at the meeting.

The information in this article is based on a press release statement and details from the company’s Form 8-K filed with the Securities and Exchange Commission.

In other recent news, Xtant Medical Holdings Inc. reported a surprising profit for the second quarter of 2025. The company achieved earnings per share of $0.02, surpassing the forecasted loss of $0.01. Additionally, Xtant Medical’s revenue exceeded expectations, reaching $35.4 million compared to the anticipated $31.35 million. In another development, Xtant Medical announced the commercial launch of CollagenX, a bovine collagen particulate product designed for surgical wound closure. According to the company, this new product aims to promote healing, prevent wound separation, and address concerns related to surgical site infections. These recent developments reflect the company’s strategic initiatives in expanding its product offerings and improving its financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.